系统性红斑狼疮合并纯红细胞再生障碍性贫血1例报道及文献复习

doi:10.3969/j.issn.1674-8115.2024.02.015

上海交通大学学报（医学版） ›› 2024, Vol. 44 ›› Issue (2): 278-286.doi: 10.3969/j.issn.1674-8115.2024.02.015

• 病例报告 • 上一篇

系统性红斑狼疮合并纯红细胞再生障碍性贫血1例报道及文献复习

陈琼¹(), 方杰², 魏强华¹()

^1.上海交通大学医学院附属第一人民医院中医科，上海 200080
^2.上海交通大学医学院附属第一人民医院检验科，上海 200080

收稿日期:2023-07-23 接受日期:2023-12-26 出版日期:2024-02-28 发布日期:2024-03-25
通讯作者: 魏强华 E-mail:chenqiongjone@163.com;weiqh1122@sina.com
作者简介:陈琼（1987—），女，主治医师，硕士；电子信箱：chenqiongjone@163.com。
基金资助:
国家自然科学基金(82104908)

Systemic lupus erythematosus complicated with pure red cell aplasia: a case report and literature review

CHEN Qiong¹(), FANG Jie², WEI Qianghua¹()

^1.Department of Traditional Chinese Medicine, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200080, China
^2.Department of Laboratory, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200080, China

Received:2023-07-23 Accepted:2023-12-26 Online:2024-02-28 Published:2024-03-25
Contact: WEI Qianghua E-mail:chenqiongjone@163.com;weiqh1122@sina.com
Supported by:
National Natural Science Foundation of China(82104908)

摘要/Abstract

摘要：

该文对1例系统性红斑狼疮（systemic lupus erythematosus，SLE）合并纯红细胞再生障碍性贫血（pure red cell aplasia，PRCA）病例进行报道，并复习1974—2021年国内外文献报道的51例SLE合并PRCA患者的资料，对该52例患者（51+1例）的流行病学特征、临床特征、实验室指标、治疗以及预后进行统计分析。结果显示，52例患者多见于亚洲育龄期女性。诊断为SLE和诊断为PRCA时，患者的中位年龄分别为31.5岁和36.0岁。先诊断为SLE的患者，诊断为SLE与诊断为PRCA的间隔时间明显长于先诊断为PRCA的患者（P=0.042）。52例患者临床表现多为乏力、关节痛、雷诺现象和皮疹，并可合并自身免疫性溶血性贫血（autoimmune hemolytic anemia，AIHA）、胸腺瘤、甲状腺功能减退、重症肌无力（myasthenia gravis，MG）。实验室指标中抗核抗体（antinuclear antibody，ANA）阳性、抗双链DNA（double stranded DNA，dsDNA）抗体阳性、尿蛋白阳性和低补体水平的人数比例均较高。52例患者中，有51例的治疗方案包含糖皮质激素，占比98.08%，其次依次为输血治疗、环孢素A、环磷酰胺、高剂量静脉注射免疫球蛋白等。在报道了预后的50例病例中，预后好转44例，无效和死亡各3例。该文旨在提高临床医师对SLE合并PRCA的认识。

关键词: 系统性红斑狼疮, 纯红细胞再生障碍性贫血, 流行病学特征, 临床特征

Abstract:

This article reports a single case of a patient with systemic lupus erythematosus (SLE) combined with pure red cell aplasia (PRCA), and reviews 51 additional cases of patients reported by domestic and overseas papers from 1974 to 2021. These 52 (51+1) cases were analyzed to summarize the epidemiological features, clinical features, laboratory inspections, treatments and prognosis of the patients. The results indicated that among all the 52 cases, cases of SLE combined with PRCA were mostly seen in Asian childbearing age women. The median ages of patients diagnosed with SLE and diagnosed with PRCA were 31.5 years and 36.0 years, respectively. The time interval between the initial diagnosis of SLE and subsequent diagnosis of PRCA was significantly longer than the interval for the initial diagnosis of PRCA, suggesting a delayed onset of SLE in these patients (P=0.042). Various clinical features of the 52 patients were reported, including mostly fatigue, joint pains, Raynaud phenomena and rashes, and SLE maybe combined with autoimmune hemolytic anemia (AIHA), thymoma, hypothyroidism and myasthenia gravis (MG). In these reported cases, laboratory indicators showed higher proportions of antinuclear antibody (ANA), anti double stranded DNA antibody (anti-dsDNA antibody), positive urinary protein and low complement levels. Among the 52 patients, 51 cases (98.08%) were treated with glucocorticoids, followed by blood transfusion, cyclosporin A, cyclophosphamide and high-dose intravenous immunoglobulin. Of the 50 patients whose prognoses were reported, 44 showed improvement, while 3 treatments were not effective and 3 resulted in death. This article aims to enhance the understanding of SLE combined with PRCA among doctors.

Key words: systematic lupus erythrematosus (SLE), pure red cell aplasic anemia (PRCA), epidemiological characteristic, clinical characteristic

中图分类号:

R593.24

陈琼, 方杰, 魏强华. 系统性红斑狼疮合并纯红细胞再生障碍性贫血1例报道及文献复习[J]. 上海交通大学学报（医学版）, 2024, 44(2): 278-286.

CHEN Qiong, FANG Jie, WEI Qianghua. Systemic lupus erythematosus complicated with pure red cell aplasia: a case report and literature review[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2024, 44(2): 278-286.

图/表 6

图1 病情变化和治疗过程图Note： CsA—cyclosporine A; Pred—prednisone; MPS—methylprednisolone; Hb—hemoglobin; Ret—reticulocyte.

Fig 1 Process of disease change and treatment

表1 51例病例资料

Tab 1 Data of the 51 cases

First author	Published year	Origin of the case	Case sample/n	Gender	Age/year	Reference
ZHANG L	2005	China	1	F	6	[6]
ZHANG G C	1991	China	1	M	44	[7]
XIE Q B	2002	China	2	M/F	54/56	[8]
CHEN N N	2006	China	1	F	26	[9]
LIU G Q	2005	China	2	F/F	41/31	[10]
HUANG R W	1998	China	1	F	43	[11]
LIU W F	1999	China	1	F	21	[12]
LIU Y	2017	China	1	M	19	[13]
NI X	2011	China	1	F	37	[14]
MITSUNAKA H	1998	Japan	1	F	68	[15]
IWADATE H	2006	Japan	1	F	43	[16]
HABIB G S	2002	Iseral	1	F	31	[17]
LINARDAKI G D	1999	Greece	2	F/F	21/28	[18]
KOYAMA R V	2014	Brazil	1	F	52	[19]
CHOI B G	2002	Korea	1	F	31	[20]
DUCHMANN R	1995	Germany	1	F	63	[21]
FRANCIS D A	1982	UK	1	F	64	[22]
OKADA H	1994	Japan	1	M	43	[23]
MAVRAGANI C P	2003	Greece	1	F	38	[24]
KIELY P D	1995	India	2	F/F	22/33	[25]
ATZENI F	2003	Italy	1	F	50	[26]
DUARTE-SALAZAR C	2000	Mexico	1	F	21	[27]
CHAN A Y K	2005	Hongkong, China	1	F	59	[28]
IDEGUCHI H	2007	Japan	1	F	82	[29]
SUZUKI T	2003	Japan	1	F	54	[30]
GUPTA R K	2011	Vietnam	1	F	23	[31]
FRANZÉN P	1987	Finland	1	F	24	[32]
HECK L W	1985	USA	1	F	17	[33]
HARA A	2008	Japan	1	F	42	[34]
MARMONT A M	2014	Italy	1	F	45	[35]
MEYER R J	1978	China	1	F	56	[36]
FALLAHI S	2014	Iran	1	F	54	[37]
ARCASOY M O	2005	USA	1	F	34	[38]
MOLLAEIAN A	2020	African	1	M	65	[39]
BISWAL N	2007	India	1	F	9	[40]
NAKAMURA H	2010	Japan	1	F	47	[41]
ILAN Y	1993	Iseral	1	F	22	[42]
TAKIGAWA M	1974	Japan	1	F	44	[43]
HARADA N	1990	Japan	1	F	27	[44]
ATSUMI T	1991	Japan	1	M	21	[45]
JAREK M J	1996	USA	1	F	69	[46]
MINAMI R	2006	Japan	1	F	33	[47]
MURAYAMA J	2006	Japan	1	F	48	[48]
SAEED M	2021	Pakistan	1	F	27	[49]
TOMAC-STOJMENOVIĆ M	2017	Croatia	1	F	35	[50]
DU A X	2006	Taiwan, China	1	F	24	[51]
JIMENO S A	2001	Spain	1	F	19	[52]

图2 病例来源地区分布（左）及女性患者年龄分布（右）

Fig 2 Regional distribution of cases (left) and age distribution of female patients (right)

表2 诊断为SLE/PRCA时的患者特征

Tab 2 Characteristics of patients diagnosed with SLE/PRCA

Demographic data	Number of patient/n (%)	Age/year	Interval between two diagnoses/year
Diagnosed as SLE first	22 (43.71)	35.77 $±$ 14.19	6.95 $±$ 5.64^①
Diagnosed as PRCA first	12 (23.08)	30.83 $±$ 16.24	3.22 $±$ 2.92
Diagnosed as SLE and PRCA simultaneously	18 (34.62)	37.22 $±$ 16.51	0

表2 诊断为SLE/PRCA时的患者特征

Tab 2 Characteristics of patients diagnosed with SLE/PRCA

Demographic data	Number of patient/n (%)	Age/year	Interval between two diagnoses/year
Diagnosed as SLE first	22 (43.71)	35.77 $±$ 14.19	6.95 $±$ 5.64^①
Diagnosed as PRCA first	12 (23.08)	30.83 $±$ 16.24	3.22 $±$ 2.92
Diagnosed as SLE and PRCA simultaneously	18 (34.62)	37.22 $±$ 16.51	0

表3 实验室指标

Tab 3 Laboratory indicators

Laboratory indicator	Positive case/ reported case/n	Positive rate/%
ANA	47/47	100.00
Anti-dsDNA antibody	38/43	88.37
Hypocomplementemia	32/39	82.05
Urinary protein	23/33	69.69
ACA	10/20	50.00
Anti-Sm antibody	7/18	38.89

表4 治疗措施

Tab 4 Treatment measures

Treatment	Number of patient/n (%)
GC	51 (98.08)
BT	34 (65.38)
CsA	13 (25.00)
IVIG	9 (17.31)
CTX	9 (17.31)
HCQ	8 (15.38)
EPO	5 (9.62)
AZA	5 (9.62)
MMF	2 (3.85)
PE	2 (3.85)
RTX	2 (3.85)
MTX	1 (1.92)

参考文献 53

1	CHAKRAVARTY E F, BUSH T M, MANZI S, et al. Prevalence of adult systemic lupus erythematosus in California and Pennsylvania in 2000: estimates obtained using hospitalization data[J]. Arthritis Rheum, 2007, 56(6): 2092-2094.
2	PONS-ESTEL G J, ALARCÓN G S, SCOFIELD L, et al. Understanding the epidemiology and progression of systemic lupus erythematosus[J]. Semin Arthritis Rheum, 2010, 39(4): 257-268.
3	IZMIRLY P M, PARTON H, WANG L, et al. Prevalence of systemic lupus erythematosus in the United States: estimates from a meta-analysis of the centers for disease control and prevention national lupus registries[J]. Arthritis Rheumatol, 2021, 73(6): 991-996.
4	STOJAN G, PETRI M. Epidemiology of systemic lupus erythematosus: an update[J]. Curr Opin Rheumatol, 2018, 30(2): 144-150.
5	中华医学会血液学分会红细胞疾病(贫血)学组. 获得性纯红细胞再生障碍诊断与治疗中国专家共识(2020年版)[J]. 中华血液学杂志, 2020, 41(3): 177-184.
	Red Blood Cell Disease (Anemia) Group, Chinese Society of Hematology, Chinese Medical Association. Chinese expert consensus on the diagnosis and treatment of acquired pure red cell aplasia (2020)[J]. Chinese Journal of Hematology, 2020, 41(3): 177-184.
6	张丽, 邹尧, 陈玉梅, 等. 儿童系统性红斑狼疮相关纯红细胞再生障碍性贫血1例报告并文献复习[J]. 中国实用儿科杂志, 2005, 20(7): 436-438.
	ZHANG L, ZOU Y, CHEN Y M, et al. Pure red cell aplasia as presentation of systemic lupus erythematosus in children[J]. Chinese Journal of Practical Pediatrics, 2005, 20(7): 436-438.
7	张国材. 继发于系统性红斑性狼疮的纯红细胞性再生障碍性贫血1例报告[J]. 新医学, 1991, 22(4): 187.
	ZHANG G C. A case report of pure red blood cell aplastic anemia secondary to systemic lupus erythematosus[J]. Journal of New Medicine, 1991, 22(4): 187.
8	谢其冰, 杨南萍, 罗泽玲. 系统性红斑狼疮伴纯红细胞再生障碍性贫血2例[J]. 实用医学杂志, 2002, 18(8): 865.
	XIE Q B, YANG N P, LUO Z L, et al. Two cases of systemic lupus erythematosus with pure red blood cell aplastic anemia[J]. The Journal of Practical Medicine, 2002, 18(8): 865.
9	陈楠楠, 黄世林, 向阳, 等. 系统性红斑狼疮并发纯红细胞再生障碍性贫血[J]. 临床皮肤科杂志, 2006, 35(8): 536.
	CHEN N N, HUANG S L, XIANG Y, et al. Systemic lupus erythematosus complicated with pure red blood cell aplastic anemia[J]. Journal of Clinical Dermatology, 2006, 35(8): 536.
10	刘国强. 系统性红斑狼疮并发纯红细胞再生障碍性贫血2例[J]. 中国实用内科杂志, 2005, 25(10): 958.
	LIU G Q. Two cases of systemic lupus erythematosus complicated with pure red blood cell aplastic anemia[J]. Chinese Journal of Practical Internal Medicine, 2005, 25(10): 958.
11	黄仁魏, 夏忠军, 吴祥元, 等. 以纯红细胞再生障碍性贫血为首发表现的系统性红斑狼疮1例[J]. 中国实用内科杂志, 1998, 18(9): 551.
	HUANG R W, XIA Z J, WU X Y, et al. A case of systemic lupus erythematosus with pure red blood cell aplastic anemia as the initial manifestation[J]. Chinese Journal of Practical Internal Medicine, 1998, 18(9): 551.
12	刘维凤, 吴恩亮. 以纯红细胞再生障碍性贫血为首发症状的系统性红斑狼疮1例[J]. 滨州医学院学报, 1999, 22(6): 620.
	LIU W F, WU E L. A case of systemic lupus erythematosus with pure red blood cell aplastic anemia as the initial symptom[J]. Journal of Binzhou Medical University, 1999, 22(6): 620.
13	刘艳, 高华, 任虹蓉, 等. 重症系统性红斑狼疮合并纯红细胞再生障碍性贫血1例[J]. 武警后勤学院学报(医学版), 2017, 26(9): 823-824.
	LIU Y, GAO H, REN H R, et al. A case of severe systemic lupus erythematosus complicated with pure red blood cell aplastic anemia[J]. Journal of Logistics University of PAP (Medical Sciences), 2017, 26(9): 823-824.
14	倪勋, 魏锦, 罗文丰. 系统性红斑狼疮继发纯红细胞再生障碍一例[J]. 华西医学, 2011, 26(8): 1211-1212.
	NI X, WEI J, LUO W F. A case of secondary pure red blood cell regeneration disorder in systemic lupus erythematosus[J]. West China Medical Journal, 2011, 26(8): 1211-1212.
15	MITSUNAKA H, TOKUDA M, TAKAHARA J, et al. A case of systemic lupus erythematosus with pure red cell aplasia possibly caused by persistent infection of human parvovirus B19[J]. Nihon Rinsho Meneki Gakkai Kaishi, 1998, 21(5): 220-225.
16	IWADATE H, KOBAYASHI H, SHIO K, et al. A case of systemic lupus erythematosus complicated by pure red cell aplasia and idiopathic portal hypertension after thymectomy[J]. Mod Rheumatol, 2006, 16(2): 109-112.
17	HABIB G S, SALIBA W R, FROOM P. Pure red cell aplasia and lupus[J]. Semin Arthritis Rheum, 2002, 31(4): 279-283.
18	LINARDAKI G D, BOKI K A, FERTAKIS A, et al. Pure red cell aplasia as presentation of systemic lupus erythematosus: antibodies to erythropoietin[J]. Scand J Rheumatol, 1999, 28(3): 189-191.
19	KOYAMA R V, SILVA L F, HENRIQUES V B, et al. Pure red cell aplasia associated with systemic lupus erythematosus[J]. Acta Reumatol Port, 2014, 39(3): 265-268.
20	CHOI B G, YOO W H. Successful treatment of pure red cell aplasia with plasmapheresis in a patient with systemic lupus erythematosus[J]. Yonsei Med J, 2002, 43(2): 274-278.
21	DUCHMANN R, SCHWARTING A, PORALLA T, et al. Thymoma and pure red cell aplasia in a patient with systemic lupus erythematosus[J]. Scand J Rheumatol, 1995, 24(4): 251-254.
22	FRANCIS D A. Pure red-cell aplasia: association with systemic lupus erythematosus and primary autoimmune hypothyroidism[J]. Br Med J (Clin Res Ed), 1982, 284(6309): 85.
23	OKADA H, SUZUKI H, UCHIDA H, et al. Acquired idiopathic pure red cell aplasia in a hemodialyzed patient with inactive systemic lupus erythematosus[J]. Intern Med, 1994, 33(8): 492-495.
24	MAVRAGANI C P, VLACHAKI E, VOULGARELIS M. Pure red cell aplasia in a Sjögren's syndrome/lupus erythematosus overlap patient[J]. Am J Hematol, 2003, 72(4): 259-262.
25	KIELY P D, MCGUCKIN C P, COLLINS D A, et al. Erythrocyte aplasia and systemic lupus erythematosus[J]. Lupus, 1995, 4(5): 407-411.
26	ATZENI F, SARZI-PUTTINI P, CAPSONI F, et al. Successful treatment of pure red cell aplasia in systemic lupus erythematosus with cyclosporin A[J]. Clin Exp Rheumatol, 2003, 21(6): 759-762.
27	DUARTE-SALAZAR C, CAZARÍN-BARRIENTOS J, GOYCOCHEA-ROBLES M V, et al. Successful treatment of pure red cell aplasia associated with systemic lupus erythematosus with cyclosporin A[J]. Rheumatology (Oxford), 2000, 39(10): 1155-1157.
28	CHAN A Y K, LI E K, TAM L S, et al. Successful treatment of pure red cell aplasia associated with systemic lupus erythematosus with oral danazol and steroid[J]. Rheumatol Int, 2005, 25(5): 388-390.
29	IDEGUCHI H, OHNO S, ISHIGATSUBO Y. A case of pure red cell aplasia and systemic lupus erythematosus caused by human parvovirus B19 infection[J]. Rheumatol Int, 2007, 27(4): 411-414.
30	SUZUKI T, SAITO S, HIRABAYASHI Y, et al. Human parvovirus B19 infection during the inactive stage of systemic lupus erythematosus[J]. Intern Med, 2003, 42(6): 538-540.
31	GUPTA R K, EZEONYEJI A N, THOMAS A S, et al. A case of pure red cell aplasia and immune thrombocytopenia complicating systemic lupus erythematosus: response to rituximab and cyclophosphamide[J]. Lupus, 2011, 20(14): 1547-1550.
32	FRANZÉN P, FRIMAN C, PETTERSSON T, et al. Combined pure red cell aplasia and primary autoimmune hypothyroidism in systemic lupus erythematosus[J]. Arthritis Rheum, 1987, 30(7): 839-840.
33	HECK L W, ALARCÓN G S, BALL G V, et al. Pure red cell aplasia and protein-losing enteropathy in a patient with systemic lupus erythematosus[J]. Arthritis Rheum, 1985, 28(9): 1059-1061.
34	HARA A, WADA T, KITAJIMA S, et al. Combined pure red cell aplasia and autoimmune hemolytic anemia in systemic lupus erythematosus with anti-erythropoietin autoantibodies[J]. Am J Hematol, 2008, 83(9): 750-752.
35	MARMONT A M, BACIGALUPO A, GUALANDI F, et al. Systemic lupus erythematosus complicated with thymoma and pure red cell aplasia (PCRA). CR of both complications following thymectomy and allogeneic haematopoietic SCT (HSCT), but persistence of antinuclear antibodies (ANA)[J]. Bone Marrow Transplant, 2014, 49(7): 982-983.
36	MEYER R J, HOFFMAN R, ZANJANI E D. Autoimmune hemolytic anemia and periodic pure red cell aplasia in systemic lupus erythematosus[J]. Am J Med, 1978, 65(2): 342-345.
37	FALLAHI S, AKBARIAN M, DABIRI S. Pure red cell aplasia as a presenting feature in systemic lupus erythematosus and association with thymoma, hypothyroidism and hypoparathyroidism: a case report and literature review[J]. Iran J Allergy Asthma Immunol, 2014, 13(2): 138-143.
38	ARCASOY M O, CHAO N J. T-cell-mediated pure red-cell aplasia in systemic lupus erythematosus: response to cyclosporin A and mycophenolate mofetil[J]. Am J Hematol, 2005, 78(2): 161-163.
39	MOLLAEIAN A, HAAS C. A tale of autoimmunity: thymoma, thymectomy, and systemic lupus erythematosus[J]. Clin Rheumatol, 2020, 39(7): 2227-2234.
40	BISWAL N, NARAYANAN P, CHETAN G. Cyclosporine A responsive pure red cell aplasia in a child with systemic lupus erythematosus[J]. Indian J Hematol Blood Transfus, 2007, 23(3/4): 107-108.
41	NAKAMURA H, OKADA A, KAWAKAMI A, et al. Isoniazid-triggered pure red cell aplasia in systemic lupus erythematosus complicated with myasthenia gravis[J]. Rheumatol Int, 2010, 30(12): 1643-1645.
42	ILAN Y, NAPARSTEK Y. Pure red cell aplasia associated with systemic lupus erythematosus: remission after a single course of intravenous immunoglobulin[J]. Acta Haematol, 1993, 89(3): 152-154.
43	TAKIGAWA M, HAYAKAWA M. Thymoma with systemic lupus erythematosus, red blood cell aplasia, and herpesvirus infection[J]. Arch Dermatol, 1974, 110(1): 99-102.
44	HARADA N, NAGASAWA K, OKAMURA T, et al. A case of systemic lypus erythematosus with autoimmune hemolytic anemia amd with a history of pure red cell aplasia[J]. Jpn J Clin Immunol, 1990, 13(3): 286-291.
45	ATSUMI T, SAGAWA A, KATSUMATA K, et al. A case of systemic lupus erythematosus with pure red cell aplasia responded to steroid pulse therapy[J]. Jpn J Clin Immunol, 1991, 14(6): 639-645.
46	JAREK M J, ENZENAUER R J, JUDSON P H. Pure red cell aplasia in systemic lupus erythematosus[J]. J Clin Rheumatol, 1996, 2(1): 44-49.
47	MINAMI R, IZUTSU K, MIYAMURA T, et al. A case of systemic lupus erythematosus accompanied with pure red cell aplasia[J]. Nihon Rinsho Meneki Gakkai Kaishi, 2006, 29(3): 148-153.
48	MURAYAMA J, ASANUMA Y, TSUDA T, et al. Appearance of central nervous system lupus during corticosteroid therapy and warfarinization in a patient with pure red cell aplasia and antiphospholipid syndrome[J]. Nihon Rinsho Meneki Gakkai Kaishi, 2006, 29(1): 43-47.
49	SAEED M, SHARIF F, IJAZ M, et al. A case of systemic lupus erythematosus presenting as pure red cell aplasia[J]. Int J Hematol Oncol Stem Cell Res, 2021, 15(2): 135-138.
50	TOMAC-STOJMENOVIĆ M, HADŽISEJDIĆ I, VALKOVIĆ T, et al. Pure red blood cell aplasia in systemic lupus erythematosus: a case report[J]. Reumatizam, 2017, 64(1): 26-29.
51	杜安琇, 叶凤英, 高雅慧. Azathioprine引起的单纯红血球再生不良[J]. 台湾医学, 2006, 10(1): 42-48.
	DU A X, YE F Y, GAO Y H. Azathioprine-induced pure red blood cell aplasia[J]. Formosan Journal of Medicine, 2006, 10(1): 42-48.
52	JIMENO SAINZ A, BLÁZQUEZ ENCINAR J C, CONESA V. Pure red aplasia as the first manifestation of systemic lupus erythematosus[J]. Am J Med, 2001, 111(1): 78-79.
53	CHOI Y, JO J C, JEON H J, et al. Trend and treatment patterns of aplastic anemia in Korea, pure red cell aplasia and myelodysplastic syndrome in Korea: a nation-wide analysis[J]. Int J Hematol, 2017, 106(4): 500-507.

[1]	杨婧偊, 陈留宝, 王康太, 杨兴智, 于海涛. 基于实验室指标的系统性红斑狼疮鉴别诊断列线图的构建及评估[J]. 上海交通大学学报（医学版）, 2024, 44(2): 204-211.
[2]	赵洁, 姜言, 郝思国. 弥漫大B细胞淋巴瘤患者临床特征及预后分析[J]. 上海交通大学学报（医学版）, 2023, 43(10): 1282-1288.
[3]	韩夏夏, 蒋扬, 顾霜霜, 戴黛, 沈南. 系统性红斑狼疮患者免疫细胞代谢通路转录组分析[J]. 上海交通大学学报（医学版）, 2022, 42(9): 1197-1207.
[4]	丁思奇, 黄啸君, 詹飞霞, 田沃土, 曹立. ATP1A2基因突变所致的偏瘫型偏头痛2例报道[J]. 上海交通大学学报（医学版）, 2022, 42(8): 1158-1162.
[5]	谢依热·哈木拉提null, 赵倩, 李丞, 宋宁, 王颖, 古丽洁合热·吐尔逊null, 卜军, 杨毅宁, 李晓梅. 基于真实世界的缺血性心脑血管共患疾病的临床特征及卫生经济学评价[J]. 上海交通大学学报（医学版）, 2022, 42(6): 778-785.
[6]	胡佳宁, 张锦文, 刘晓瑞, 陈彩莲, 林羿. 难治性产后出血导致子宫切除的危险因素分析[J]. 上海交通大学学报（医学版）, 2022, 42(4): 409-414.
[7]	李佳, 王然, 鲍春德, 沈南, 扶琼. 简化整体抗磷脂抗体综合征评分在系统性红斑狼疮患者新发血栓栓塞事件风险评估中的应用研究[J]. 上海交通大学学报(医学版), 2021, 41(8): 1046-1050.
[8]	刘音, 杨涛, 谢裕赛, 王玉柱. 基于GEO数据库筛选狼疮性肾炎的关键基因和信号通路[J]. 上海交通大学学报(医学版), 2021, 41(6): 749-755.
[9]	赵倩, 张美玉, 季萍, 汪佳远, 王树军, 刘帅, 王颖. 细胞间黏附分子-1在CD4⁺T细胞辅助B细胞产生抗体中的作用和临床意义[J]. 上海交通大学学报(医学版), 2021, 41(5): 588-594.
[10]	黄道, 韦栋, 徐志红, 胡家安. 老年呼吸道病毒感染119例临床特征分析[J]. 上海交通大学学报(医学版), 2021, 41(5): 628-631.
[11]	耿时凯, 张乐, 王慧静, 吕良敬, 万伟国, 孙芳芳, 叶霜. 探索二甲双胍减少系统性红斑狼疮患者感染事件的作用：一项Met-Lupus研究的事后分析[J]. 上海交通大学学报(医学版), 2021, 41(4): 473-478.
[12]	冯泽豪, 柴烨子, 苏璇, 孙宝航行, 刘启明, 姜萌, 卜军. 体质量指数对系统性红斑狼疮患者心肌累及的影响[J]. 上海交通大学学报(医学版), 2021, 41(2): 180-186.
[13]	马银珠，陆光华，钟娜，王海红，和申，赵雪，江海峰，王振. 酒精所致精神病性障碍男性患者临床特征及危险因素[J]. 上海交通大学学报(医学版), 2020, 40(9): 1256-1262.
[14]	徐宁，周甜，侯国俊，沈南，唐元家. 长链非编码RNA AC073046.25在系统性红斑狼疮易感基因TET3表达调节中的作用[J]. 上海交通大学学报(医学版), 2020, 40(8): 1030-1035.
[15]	祖娟，钱方媛，吴迪，谢新欣，任庆国，张志珺. 成年晚发型糖原贮积症Ⅱ型临床特征及基因突变分析[J]. 上海交通大学学报(医学版), 2020, 40(8): 1108-1112.

系统性红斑狼疮合并纯红细胞再生障碍性贫血1例报道及文献复习

Systemic lupus erythematosus complicated with pure red cell aplasia: a case report and literature review

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

图/表 6

参考文献 53

相关文章 15

编辑推荐

Metrics